



(86) Date de dépôt PCT/PCT Filing Date: 2012/09/10

(87) Date publication PCT/PCT Publication Date: 2013/03/14

(45) Date de délivrance/Issue Date: 2023/09/26

(85) Entrée phase nationale/National Entry: 2014/02/24

(86) N° demande PCT/PCT Application No.: CA 2012/000832

(87) N° publication PCT/PCT Publication No.: 2013/033828

(30) Priorité/Priority: 2011/09/09 (US61/532,808)

(51) Cl.Int./Int.Cl. *A61K 36/77* (2006.01),
A23L 29/30 (2016.01), *A23L 33/00* (2016.01),
A23L 33/105 (2016.01), *A23L 33/125* (2016.01),
A61P 1/16 (2006.01), *C13B 50/00* (2011.01)




(72) Inventeurs/Inventors:
POTVIN, STEEVES, CA;
BELAND, FRANCOIS, CA;
BELAND, GENEVIEVE, CA;
ABE, KEIKO, JP;
BEDARD, VINCENT, CA

(73) Propriétaire/Owner:
PRODUCTEURS ET PRODUCTRICES ACERICOLES
DU QUEBEC, CA

(74) Agent: BENOIT & COTE INC.

(54) Titre : EXTRAIT DE SIROP D'ERABLE COMME COMPOSITION HEPATOPROTECTRICE

(54) Title: MAPLE SYRUP EXTRACT AS A HEPATOPROTECTIVE COMPOSITION



(n = 8~9) (* P < 0.05)

AST (GOT): aspartate aminotransferase

ALT (GPT): alanine aminotransferase

LDH : lactate dehydrogenase

(57) Abrégé/Abstract:

The present document describes a nutriprotective diet comprising a nutriprotective amount of a sugar plant syrup, a sugar plant syrup extract, a sugar plant extract, or combinations thereof. The present document also describes a method of eliciting a nutriprotective effect in a subject, which comprises administering a nutriprotective amount of a nutriprotective diet according to the present invention. Also, the present document also describes a method of treating a subject with a disorder, by administering a nutriprotective amount of a nutriprotective diet according to the present invention. Also, the present document describes a process for the extraction of polyphenolic compounds from maple syrup using adsorbent materials, and the extracts obtained therefrom.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2013/033828 A1

(43) International Publication Date
14 March 2013 (14.03.2013)

(51) International Patent Classification:

A61K 36/77 (2006.01) *C13B 50/00* (2011.01)
A23L 1/09 (2006.01)

(21) International Application Number:

PCT/CA2012/000832

(22) International Filing Date:

10 September 2012 (10.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/532,808 9 September 2011 (09.09.2011) US

(71) Applicant (for all designated States except US):

**FÉDÉRATION DES PRODUCTEURS ACÉRIQUES
DU QUÉBEC** [CA/CA]; Maison de l'UPA, 555, boul. Ro-
land-Therrien, bureau 525, Longueuil, Québec J4H 4G5
(CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **POTVIN, Steeves**

[CA/CA]; 9580 Nantel, Québec, Québec G2B 5A2 (CA).
BÉDARD, Vincent [CA/CA]; 7735, rue du Daim unité
503, Québec, Québec G1G 0B1 (CA). **BÉLAND, François**
[CA/CA]; 928, rue Du Giron, L'Ancienne-Lorette, Québec
G2E 6L4 (CA). **BÉLAND, Geneviève** [CA/CA]; 2460, rue
Payan, Saint-Hyacinthe, Québec J2S 4B3 (CA). **ABE,**

Keiko [JP/JP]; 1-16-15 Minamimachi, Saitama, Saitama
3350003 (JP).

(74) Agent: **BENOÎT & CÔTÉ, ASSOCIÉS INC.**; 1550,
Metcalfé, bureau 800, Montréal, Québec H3A 3P1 (CA).

(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NUTRIPROTECTIVE DIET




Fig. 3

(57) **Abstract:** The present document describes a nutritive diet comprising a nutritive amount of a sugar plant syrup, a sugar plant syrup extract, a sugar plant extract, or combinations thereof. The present document also describes a method of eliciting a nutritive effect in a subject, which comprises administering a nutritive amount of a nutritive diet according to the present invention. Also, the present document also describes a method of treating a subject with a disorder, by administering a nutritive amount of a nutritive diet according to the present invention. Also, the present document describes a process for the extraction of polyphenolic compounds from maple syrup using adsorbent materials, and the extracts obtained therefrom.

WO 2013/033828 A1

WO 2013/033828 A1

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

Title: Maple Syrup Extract as a Hepatoprotective Composition

BACKGROUND

(a) Field

[0002] The present document describes a nutriprotective diet comprising a nutriprotective amount of a sugar plant syrup, a sugar plant syrup extract, a sugar plant extract, a rejection of a sugar plant extract, or combinations thereof. The present document also describes a method of eliciting a nutriprotective effect in a subject, which comprises administering a nutriprotective amount of a nutriprotective diet according to the present invention. Also, the present document also describes a method of treating a subject with a disorder, by administering a nutriprotective amount of a nutriprotective diet according to the present invention. Also, the present document describes a process for the extraction of polyphenolic compounds from maple syrup using adsorbent materials, and the extracts obtained therefrom.

(b) Related Prior Art

[0003] Maple syrup (MS), a natural sweetener consumed as a palatable sweetener, is obtained by concentrating the sap collected from certain maple species including the sugar maple (*Acer saccharum*), which is native to North America. It is a very popular food product preferred by a large number of children, adults and even elderly people in the world.

[0004] With the realization that diets and lifestyle of different populations may determine their rates of cancer and other diseases, more and more individuals try to increase their intake in natural products such as MS with the expectation that it may also be good for their health.

[0005] Hepatic diseases or hepatic dysfunction are known to be closely involved in all life-style related diseases such as diabetes mellitus. In addition, decreased hepatic function is pointed out as a major cause of aging. In a modern era in which people are exposed to many factors that increase active oxygen species harmful to organs such as tobacco, alcohol, high-fat diet and stress, it can be said that people live in an environment that tends to damage hepatic function. Daily diet is an important key to prevent life-style related diseases including metabolic syndrome. Continuous intake of foods with liver-protecting function may be promising for their prevention.

[0006] Liver diseases are classified according to their cause into viral liver diseases, alcoholic liver diseases, liver diseases by drug toxicity, fatty liver diseases, autoimmune liver diseases, metabolic liver diseases and other liver diseases. Liver diseases are difficult to diagnose in early stages owing to the absence of subjective symptoms, and thus are the leading causes of death in many countries. However, there is still no effective therapeutic agent and diagnostic method for liver diseases.

[0007] Many studies on the use of natural materials for the prevention and treatment of liver diseases have been conducted. Typical examples of such natural materials include silymarin isolated from the seeds of *Silybum marianum*, gomisin isolated from *Schizandra chinensis*, glycyrrhizin isolated from licorice root, and the like. However, none relate to the use of MS.

[0008] The liver being the chemical factory of the human body, it is directly affected by our food-intake. Considering the world-wide popularity of MS, and the fact there is no scientific evidence available regarding the health-promoting effect of a maple syrup-containing diet, increased knowledge of the function of MS would aid in the prevention of lifestyle-related diseases such as liver diseases.

SUMMARY

[0009] According to an embodiment, there is provided a nutriprotective diet comprising a nutriprotective amount of a sugar plant syrup, a sugar plant syrup

extract, a sugar plant extract, a rejection of a plant extract, or combinations thereof

[0010] The nutriprotective amount of sugar plant syrup may be at least 1 % sugar plant syrup up to 99 % sugar plant syrup.

[0011] The nutriprotective amount of sugar plant syrup may be at least 10% sugar plant syrup up to 70%% sugar plant syrup.

[0012] The nutriprotective amount of sugar plant syrup may be 20% sugar plant syrup.

[0013] The nutriprotective amount of a sugar plant syrup extract may be from about 0.0010% to about 0.15%of a sugar plant syrup extract.

[0014] The nutriprotective amount of a sugar plant syrup extract may be from about 0.0020% to about 0.10% sugar plant syrup extract.

[0015] The nutriprotective amount of a sugar plant syrup extract may be from about 0.0027% to about 0.1023% sugar plant syrup extract.

[0016] The sugar plant syrup may be a sugar plant syrup derived products. The sugar plant syrup derived products may be butter, granulated sugar, hardened sugar, soft sugar, taffy, sugar plant syrup filtration residue, rejection of product generation, or combinations thereof.

[0017] The sugar plant extract may be concentrated sugar plant water issued from reverse osmosis, concentrated sugar plant water issued from pre-boiling nanofiltration, pasteurized sugar plant water, sterilized sugar plant water and extracts from sap, concentrated sap, a sugar plant syrup, a syrup filtration residue, samara, fruits, seeds, stem, leaves, twigs, roots, heartwood, sap wood, and bark, a rejection residue from the preparation of any one of the extracts, or combinations thereof.

[0018] The sugar plant may be chosen from maple tree, birch tree, sugar cane, sugar beet, corn, rice, palm tree, and agave.

[0019] The sugar plant syrup extract may be chosen from a methanol extract, a butanol extract, a butanol extract with sugar, a butanol extract without sugar, an ethyl acetate extract, an ethanol extract, a methyl *tert*-butyl ether extract a resin purified maple syrup extract (MSX), or combinations thereof.

[0020] The sugar plant syrup extract may have a hepatoprotective effect.

[0021] The butanol extract may have a hepatoprotective effect.

[0022] In a second embodiment, there is disclosed a method of eliciting a nutriprotective effect in a subject, which comprises administering a nutriprotective amount of a diet according to the present invention.

[0023] The nutriprotective effect may be a nutrithrapy or a hepatoprotective effect.

[0024] The hepatoprotective effect may be a down-regulation in the cellular amino acid metabolism of the liver.

[0025] The hepatoprotective effect may be a down-regulation in the liver production of ammonia-forming enzymes.

[0026] The hepatoprotective effect may comprise a down-regulation in the subject serum level of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and/or lactate dehydrogenase (LDH).

[0027] In a third embodiment, there is disclosed a method of treating a subject with a disorder, which comprises administering a nutritherapeutic amount of a diet according to the present invention.

[0028] The disorder may be liver disorder, inflammatory disease, cancer, diabetes, cardio-vascular disease, neurodegenerative disease, and a memory loss.

[0029] The liver disorder may be metabolic syndrome, damaged hepatic function, hepatic acid liver, dyslipidemia, hepatitis and liver cancer.

[0030] In another embodiment, there is disclosed a use of a nutriprotective diet according to the present invention for the preparation of a medicament for the treatment of a disorder in a subject.

[0031] In another embodiment, there is disclosed a use of a nutriprotective diet according to the present invention for the treatment of a disorder in a subject.

[0032] The disorder may be liver disorder, inflammatory disease, cancer, diabetes, cardio-vascular disease, neurodegenerative disease, and a memory loss.

[0033] The liver disorder may be metabolic syndrome, damaged hepatic function, hepatic acid liver, dyslipidemia, hepatitis and liver cancer.

[0034] In another embodiment, there is disclosed a nutriprotective carrier comprising a sugar plant syrup, a sugar plant syrup extract, a sugar plant extract, or combinations thereof for synergistic uptake and/or administration of at least one dietary supplement selected from the group consisting of pharmaceutical and nutraceutical compounds, functional food, and natural health products.

[0035] The carrier may be chosen from a drinking liquid, an energy drink, a therapeutic drink, and a protein rich drink.

[0036] The carrier may be a coating on a dietary supplement.

[0037] According to another embodiment, there is provided a method of preventing or treating a disorder in a patient; which comprises administering at least one dietary supplement selected from the group consisting of pharmaceutical and nutraceutical compounds, functional food, and natural health products in combination with the carrier of the present invention, wherein the carrier is administered concurrently or prior to the supplement.

[0038] According to an embodiment, there is provided a process for the extraction of polyphenolic compounds from maple syrup, which may comprise

- a) contacting an adsorbent material having a maple syrup polyphenolic fraction adsorbed thereon with an organic solvent, for a time sufficient

and for a number of times sufficient, to elute and collect the maple syrup polyphenolic fraction.

[0039] The time sufficient may be about 30 minutes.

[0040] The number of times sufficient may be from about 1 time to about 3 times.

[0041] The process of the present in wherein prior to step a), a maple syrup mixture is adsorbed on said adsorbent material for a time sufficient to adsorb said polyphenolic fraction on said adsorbent material, wherein said mixture comprises maple syrup diluted in water.

[0042] The time sufficient to adsorb the polyphenolic fraction may be about 12 to about 20 hours.

[0043] The time sufficient to adsorb the polyphenolic fraction may be about 16 hours.

[0044] The process may be further comprising the step of diluting a maple syrup in water prior to adsorption on the adsorbent material.

[0045] The process may be further comprising the step of washing the adsorbent material with water prior to step a).

[0046] The process may be further comprising step b) :

2) heating the collected polyphenolic fraction to evaporate the organic solvent and obtain a dried polyphenolic fraction.

[0047] The heating is at a temperature of about 37°C to about 40°C.

[0048] The organic solvent is chosen from methanol, ethyl acetate, butanol, ethanol, methyl *tert*-butyl ether, and combinations thereof.

[0049] The adsorbent material may be chosen from Amberlite™ XAD-4, Amberlite™ XAD-2, Amberlite™ XAD-7, Amberlite™ XAD 7HP, Amberlite™ XAD16, Amberlite™ XAD16HP, Amberlite™ XAD761, Amberlite™ XAD1180, Amberlite™ XAD1600, Amberlite™ XFS-4257, Amberlite™ XFS-4022,

Amberlite™ XUS-40323, Amberlite™ XUS-40322, Amberlite™ FPX66, Amberlite™ strong anion exchange (SAX), Amberlite™ WAX, a pentafluorophenyl derivatived silica gel, HLB (hydrophobic-lipophilic balanced) type SILlaPrepX phase, a strong anion exchange (SAX) resin on silica, a mixed-mode strong anion exchange (SAX)-C₁₈, an aqueous C₁₈ phase, a C₁₈ phase, a C₁₈ type SILlaPrepX™ phase, diatomaceous earth.

[0050] The process may be further comprising prior to step a) an extraction with a mixture of solids for extraction of a sugar from the maple syrup.

[0051] The extraction with a mixture of solids comprises extraction with MgSO₄, NaCl, and a solid absorbent.

[0052] The solid absorbent may be chosen from an aminated silica resin, a C₁₈ silica resin, or combinations thereof.

[0053] The process may be further comprising prior to step a) a liquid-liquid extraction of said maple syrup.

[0054] The liquid-liquid extraction may comprise an ethyl acetate extraction, a butanol extraction, or combinations thereof, followed by adsorption on a silicon dioxide (SiO₂)/magnesium oxide (MgO) solid phase having a ratio of about 85% SiO₂ and about 15% MgO.

[0055] According to an embodiment, there is provided an extract obtained from the process of the present invention.

[0056] The following terms are defined below.

[0057] The term “sugar plant” is intended to mean maple tree, birch tree, sugar cane, sugar beet, corn, rice, palm tree, and agave.

[0058] The term “maple tree” is intended to mean a maple tree of a species known to date, such as *Acer nigrum*, *Acer lanum*, *Acer acuminatum*, *Acer albopurpurascens*, *Acer argutum*, *Acer barbinerve*, *Acer buergerianum*, *Acer caesium*, *Acer campbellii*, *Acer campestre*, *Acer capillipes*, *Acer cappadocicum*, *Acer carpinifolium*, *Acer caudatifolium*, *Acer caudatum*, *Acer cinnamomifolium*, *Acer circinatum*, *Acer cissifolium*, *Acer crassum*, *Acer*

crataegifolium, *Acer davidii*, *Acer decandrum*, *Acer diabolicum*, *Acer distylum*, *Acer divergens*, *Acer erianthum*, *Acer erythranthum*, *Acer fabri*, *Acer garrettii*, *Acer glabrum*, *Acer grandidentatum*, *Acer griseum*, *Acer heldreichii*, *Acer henryi*, *Acer hyrcanum*, *Acer ibericum*, *Acer japonicum*, *Acer kungshanense*, *Acer kweilinense*, *Acer laevigatum*, *Acer laurinum*, *Acer lobelii*, *Acer lucidum*, *Acer macrophyllum*, *Acer mandshuricum*, *Acer maximowiczianum*, *Acer miaoshanicum*, *Acer micranthum*, *Acer miyabei*, *Acer mono*, *Acer mono x Acer truncatum*, *Acer monspessulanum*, *Acer negundo*, *Acer ningpoense*, *Acer nipponicum*, *Acer oblongum*, *Acer obtusifolium*, *Acer oliverianum*, *Acer opalus*, *Acer palmatum*, *Acer paxii*, *Acer pectinatum*, *Acer pensylvanicum*, *Acer pentaphyllum*, *Acer pentapomicum*, *Acer pictum*, *Acer pilosum*, *Acer platanoides*, *Acer poliophyllum*, *Acer pseudoplatanus*, *Acer pseudosieboldianum*, *Acer pubinerve*, *Acer pycnanthum*, *Acer rubrum*, *Acer rufinerve*, *Acer saccharinum*, *Acer saccharum*, *Acer sempervirens*, *Acer shirasawanum*, *Acer sieboldianum*, *Acer sinopurpurescens*, *Acer spicatum*, *Acer stachyophyllum*, *Acer sterculiaceum*, *Acer takesimense*, *Acer tataricum*, *Acer tegmentosum*, *Acer tenuifolium*, *Acer tetramerum*, *Acer trautvetteri*, *Acer triflorum*, *Acer truncatum*, *Acer tschonoskii*, *Acer turcomanicum*, *Acer ukurunduense*, *Acer velutinum*, *Acer wardii*, *Acer x peronai*, *Acer x pseudoheldreichii* or any new species not yet known.

[0059] The term “sugar plant syrup” is intended to mean sugar plant syrup and sugar plant syrup derived products, such as butter, sap butter, granulated sugar, hardened sugar, soft sugar, taffy, sugar plant syrup filtration residue, and any rejection of product generation.

[0060] The term “sugar plant extract” is intended to mean extracts from the sap, samara, fruits, seeds, stem, leaves, twigs, roots, heartwood, sap wood, bark, as well as concentrated sugar plant water issued from reverse osmosis, concentrated sugar plant water issued from pre-boiling nanofiltration, pasteurized sugar plant water, and sterilized sugar plant water.

[0061] The term “sugar plant syrup extract” is intended to mean methanol extract, a butanol extract, a butanol extract with sugar, a butanol extract without sugar, an ethyl acetate extract, an ethanol extract, a methyl *tert*-butyl ether extract, extract obtained from purification resin extractions, or combinations thereof.

[0062] The term “nutriprotective” is intended to mean nutriprotective and nutritherapy of any disorders or diseases in a subject including, without limitation, liver disorder, inflammatory disease, cancer, diabetes, cardio-vascular disease and neurodegenerative disease, wherein in the case of liver it is referred to as “hepatoprotective”.

[0063] The term “dietary supplement” is also intended to mean sugar plant extracts or synthetic equivalents thereof, cosmeceutical, pharmaceutical, and neutraceutical compounds, functional food, and natural health products.

[0064] The term “hepatoprotective” is intended to mean any one of a diet, a compound, a composition, a method, a treatment with the ability to prevent damage to the liver.

[0065] Features and advantages of the subject matter hereof will become more apparent in light of the following detailed description of selected embodiments, as illustrated in the accompanying figures. As will be realized, the subject matter disclosed and claimed is capable of modifications in various respects, all without departing from the scope of the claims. Accordingly, the drawings and the description are to be regarded as illustrative in nature, and not as restrictive and the full scope of the subject matter is set forth in the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Fig. 1 illustrates the diet schedule and biological sample analysis procedure for the tested subjects.

[0067] Fig. 2 illustrates the body weight and total food intake of the tested subjects.

[0068] Fig. 3 illustrates the subjects’ blood biochemistry.

- [0069]** Fig. 4 illustrates the methods of DNA microarray data analysis.
- [0070]** Fig. 5 illustrates hierarchical clustering.
- [0071]** Fig. 6 illustrates the down-regulated genes for amino acid metabolysing enzymes.
- [0072]** Fig. 7 illustrates the down-regulation of the cellular amino acid metabolic process of ammonia-forming enzymes such as serine/threonine dehydratase and histidine ammonia-lyase.
- [0073]** Fig. 8 illustrates the experimental design of a study described herein.
- [0074]** Fig. 9 illustrates biochemical measurements analysis of a study described herein.
- [0075]** Fig. 10 illustrates biochemical measurements analysis of a study described herein.
- [0076]** Fig. 11 illustrates biochemical measurements analysis of a study described herein.
- [0077]** Fig. 12 illustrates a summary of the biochemical measurements analysis of a study described herein.
- [0078]** Fig. 13 illustrates the data of a DNA microarray analysis described herein.
- [0079]** Fig. 14 illustrates the analysis strategy of a microarray analysis described herein.
- [0080]** Fig. 15 illustrates the functional analysis of the microarray analysis described herein.
- [0081]** Fig. 16 illustrates the lipid metabolism-related genes observed in the analysis described herein.
- [0082]** Fig. 17 illustrates the inflammation and immunity related genes observed in the analysis described herein.

[0083] Fig. 18 illustrates a summary of the functional analysis performed herein.

[0084] Fig. 19 illustrates the effect of a MSE diet on the insulin signaling pathway.

[0085] Fig. 20 illustrates the effect of MSE on the insulin receptor beta subunit.

[0086] Fig. 21 illustrates the effect of MSE on the insulin receptor substrate 2.

[0087] Fig. 22 illustrates the effect of MSE on the protein kinase B (Akt).

[0088] Fig. 23 illustrates a summary of the effect of MSE on liver signaling and the associated phenotypes.

[0089] Fig. 24 illustrates the expected mechanism of action of the effect of MSE intake on liver metabolism of KK-Ay mice.

[0090] Fig. 25 illustrates the experimental design of a study described herein.

[0091] Fig. 26 illustrates experimental results of a study described herein.

[0092] Fig. 27 illustrates experimental results of a study described herein.

[0093] Fig. 28 illustrates experimental results of a study described herein.

[0094] Fig. 29 illustrates experimental results of a study described herein.

[0095] Fig. 30 illustrates experimental results of a study described herein.

[0096] Fig. 31 illustrates the experimental design of a future study.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0097] A maple syrup product (medium grade), slightly brownish in color, is provided by the Federation of Maple Syrup Producers of Quebec (Quebec, Canada). It consists of 33% water, 61.0% sucrose, 0.5% glucose, 0.3% fructose, 1.8% saccharide (oligosaccharides and polysaccharides), 0.40% protein derived

compounds, 0.25% minerals, 0.15% organic acid, 0.10% vitamins, 0.02% phenolic compounds, 0.002% amino acid, and 0.0001% phytohormones.

[0098] Three-week-old male Wistar rats, weighting about 51 g in average, are purchased from Charles River Japan (Kanagawa, Japan). They are quarantined and conditioned by administration of the AIN93G diet (Research Diets, New Brunswick, NJ, USA) for 4 days under the following conditions: temperature, $24 \pm 1^{\circ}\text{C}$; relative humidity, $48 \pm 4\%$; and artificial lighting, 12 hours/day (8:00-20:00).

[0099] Rats had free access to the diet and drinking water during this acclimatizing period. For feeding tests, they are dichotomized ($n = 7$ and 8) for maple syrup and sugar mix syrup group, respectively, and then fed for 11 days on either the AIN93G diet containing 20% maple syrup or on the 20% sugar mix syrup with a similar sugar composition (Fig. 1). The amount of maple syrup or the sugar mix syrup is arranged by taking into consideration the amounts of sucrose and β -corn starch added in each diet. Subsequently, rats in both diet groups are fasted for 16 hours, prior to being anesthetically sacrificed for dissection. Immediately after, blood sample is taken from carotid artery of each rat for the following biochemical investigations by Nagahama Life Science Laboratory (Shiga, Japan).

[00100] No significant diet difference is observed either in the total food intake or in the time-course body weight gain (Fig. 2). It should be noted that rats preferred maple syrup as well as the simulated sugar mix syrup without any sensory rejection. The serum biochemical parameters of the rats fed the maple syrup-containing diet, when compared to those fed the control, did not show significant differences in the levels of serum glucose, total cholesterol and triglyceride. While these metabolic parameters are similar to each other, there are important differences in the serum levels of aspartate aminotransferase (AST) alanine aminotransferase (ALT) and lactate dehydrogenase (LDH), as liver impairment markers (Fig. 3). In particular, there are significant decreases in AST and LDH ($P < 0.05$) (Table 1).

Table 1. Serum Biochemical Parameters[†] Investigated

	Sugar mix syrup	Maple syrup
AST, IU/L	219.4 ± 9.5	185.6 ± 10.1*
ALT, IU/L	35.5 ± 2.3	31.9 ± 1.6
LDH, IU/L	3079.5 ± 173.8	2478.0 ± 179.1*
Glucose, mg/dL	51.0 ± 7.1	51.7 ± 4.5
Total cholesterol, mg/dL	73.0 ± 3.4	80.2 ± 5.1
Triglyceride, mg/dL	66.1 ± 15.5	56.1 ± 9.8

Values are represented as the means ± SEM for n = 8 and n = 7 in the sugar mix syrup and the maple syrup, respectively.

[†] AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase.

* $P < 0.05$, for between-diet differences

[00101] A total RNA sample is prepared from the liver and 6 randomized samples are subjected to microarray analysis using GeneChip Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, CA, USA). The obtained microarray data (CEL files) are quantified with the distribution free weighted method (DFW) using the statistical language Rand Bioconductor.

[00102] All the microarray data are submitted to the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO Series ID GSE30532). To determine specific effects of maple syrup on gene expression, differentially expressed genes (DEGs) between the two groups are identified by applying the rank products (RP) method to the DFW quantified data.

[00103] Using the false discovery rate (FDR) significance < 0.05 , 246 up-regulated and 236 down-regulated genes is selected. To identify over-represented Gene Ontology (GO) terms in the DEGs, a functional annotation tool in the Database for Annotation, Visualization, and Integrated Discovery (DAVID) and QuickGO are used. GO terms with Benjamini and Hochberg FDR-corrected P -value less than 0.05 are regarded as significantly enriched. Such GO

terms for genes that are up- or down-regulated by maple syrup intake are summarized in Table 2 and Figs. 5 and 6.

Table 2. Significantly Enriched GO Term (FDR-corrected P -value ≤ 0.05) Identified among the Top 246 Up-(A) and 236 Downregulated (B) Genes

A		
GO_ID	Term	FDR-corrected P -value
0050896	response to stimulus	2.63E-02
0065007	biological regulation	
0065008	regulation of biological quality	
0010817	regulation of hormone levels	1.54E-01
0042445	hormone metabolic process	2.97E-02
0008152	metabolic process	3.18E-01
0055114	oxoacid reduction process	
0044237	cellular metabolic process	
0006082	organic acid metabolic process	3.02E-02
0043436	oxoacid metabolic process	3.70E-02
0019752	carboxylic acid metabolic process	3.70E-02
0042180	cellular ketone metabolic process	2.91E-02
0044281	small molecule metabolic process	
0002376	immune system process	
0019882	antigen processing and presentation	2.33E-01
0048002	antigen processing and presentation of peptide antigen	1.23E-01
0002474	antigen processing and presentation of peptide antigen via MHC class I	4.48E-02

B		
GO_ID	Term	FDR-corrected P -value
0050896	response to stimulus	7.59E-02
0042221	response to chemical stimulus	3.65E-02
0002376	immune system process	
0019882	antigen processing and presentation	1.55E-02
0019740	nitrogen utilization	
0009308	amine metabolic process	7.75E-02
0009310	amine catabolic process	3.20E-02
0009987	cellular process	
0044106	cellular amine metabolic process	3.67E-02
0006520	cellular amino acid metabolic process	3.83E-02
0019752	carboxylic acid metabolic process	7.21E-03
0043436	oxoacid metabolic process	7.21E-03
0042180	cellular ketone metabolic process	3.29E-03
0006082	organic acid metabolic process	3.97E-03
0044237	cellular metabolic process	8.52E-01
0044248	cellular catabolic process	3.96E-02
0009056	catabolic process	6.51E-02
0008152	metabolic process	6.81E-01

GO terms with no P -value indicate no significance.

FDR-corrected P -value of the categories appearing the deepest hierarchy are shadowed.

[00104] The up-regulated GO terms included antigen processing-presentation, carboxylic acid (including amino acid) metabolism, oxidoreduction, hormone metabolism, and response to external stimulus (Table 2A), as well as negative regulation of transcription, glutamine family amino acid metabolic process, response to organic substance, response to drug,, whereas the down-regulated GO terms comprised amine catabolism, cellular amino acid metabolism, aspartate family acid metabolic process, antigen processing-presentation and response to chemical stimulus (Table 2B).

[00105] It is noted that genes for cellular amino acid metabolic process is down-regulated, including those for ammonia-forming enzymes such as serine/threonine dehydratase and histidine ammonia-lyase (Figs. 6-7). In general, the excessive formation of free ammonia in the body is harmful to the liver, resulting in increased values of AST, ALT and LDH.

[00106] Some cases have been reported where administration of 20% casein diet activates serine/threonine dehydratase. Threonine is known as an amino acid that is difficult to metabolize and that can be better metabolized when it is ingested together with casein, leading to induction of threonine dehydratase activity for production of 2-oxobutyrate and ammonia. The high content of casein (20%) in AIN93G diet may probably enhance the activity of serine/threonine dehydratase to liberate ammonia (Figs. 6-7).

[00107] It is likely that the enhancement can be countered when the gene for this enzyme is down-regulated by administration of maple syrup. On the other hand, mRNA level of the gene for AST is down-regulated. This should also participate in down-regulation of serum AST. The present document is the first to describe a piece of body-protecting effects of ingested maple syrup.

[00108] In embodiments there are disclosed phenolic extracts and compounds from Canadian maple syrup (MS) and from maple trees (e.g. red, silver, or sugar maple). The compounds and extracts may be used for their hepatoprotective properties.

[00109] In other embodiments there are disclosed twenty-three phenolic compounds isolated from a butanol extract of Canadian maple syrup (MS) using chromatographic methods. The compounds are identified from their nuclear magnetic resonance and mass spectral data as seven lignans:

[00110] lyoniresinol (**1**), secoisolariciresinol (**2**), dehydroconiferyl alcohol (**3**), 5'-methoxy-dehydroconiferyl alcohol (**4**), erythro-guaiacylglycerol- β -O-4'-coniferyl alcohol (**5**), erythro-guaiacylglycerol- β -O-4'-dihydroconiferyl alcohol (**6**), and [3-[4-[(6-deoxy- α -L-mannopyranosyl)oxy]-3-methoxyphenyl]methyl]-5-(3,4-dimethoxyphenyl)dihydro-3-hydroxy-4-(hydroxymethyl)-2(3H)-furanone (**7**);

[00111] two coumarins: scopoletin (**8**) and fraxetin (**9**);

[00112] a stilbene: (*E*)-3,3'-dimethoxy-4,4'-dihydroxystilbene (**10**), and

[00113] thirteen phenolic derivatives: 2-hydroxy-3',4'-dihydroxyacetophenone (**11**), 1-(2,3,4-trihydroxy-5-methylphenyl)-ethanone (**12**), 2,4,5-trihydroxyacetophenone (**13**), catechaldehyde (**14**), vanillin (**15**), syringaldehyde (**16**), gallic acid (**17**), trimethyl gallic acid methyl ester (**18**), syringic acid (**19**), syringenin (**20**), (*E*)-coniferol (**21**), C-veratroylglycol (**22**), and catechol (**23**).

[00114] The antioxidant activities of the MS extract, pure compounds, vitamin C ($IC_{50}=58 \mu M$), and the synthetic commercial antioxidant, butylatedhydroxytoluene ($IC_{50}=2651 \mu M$), are evaluated in the diphenylpicrylhydrazyl (DPPH) radical scavenging assay. Among the isolates, the phenolic derivatives and coumarins showed superior antioxidant activity ($IC_{50}<100 \mu M$) compared to the lignans and stilbene ($IC_{50}>100 \mu M$).

[00115] General Experimental Procedures

[00116] 1H and ^{13}C Nuclear Magnetic Resonance (NMR) spectra are obtained either on a Bruker™ 400 MHz or a Varian™ 500 MHz instrument using deuterated methanol (CD₃OD) as solvent. Electrospray ionization mass spectral (ESIMS) data are acquired on a Q-Star Elite (Applied Biosystems MDS) mass spectrometer equipped with a Turbo Ionspray source and are obtained by direct

infusion of pure compounds. Analytical high performance liquid chromatography (HPLC) are performed on a Hitachi Elite LaChrom™ system consisting of a L2130 pump, L-2200 autosampler, and a L-2455 Diode Array Detector all operated by EZChrom™ Elite software. Semi-preparative scale HPLC are performed on a Beckman-Coulter HPLC system consisting of a Beckman System Gold™ 126 solvent module pump, 168 photodiode array (PDA)-UV/VIS detector, and 508 autosampler all operated by the 32 Karat 8.0 software. All solvents are either ACS or HPLC grade and are obtained from Wilkem Scientific (Pawcatuck, RI). Ascorbic acid (vitamin C), butylatedhydroxytoluene (BHT), and diphenylpicrylhydrazyl (DPPH) reagent are purchased from Sigma-Aldrich (St Louis, MO).

[00117] Maple Syrup (MS) Butanol Extract

[00118] Maple syrup (grade C, 20 L) is provided by the Federation of Maple Syrup Producers of Quebec (Canada). The syrup is kept frozen until extraction when it is subjected to liquid-liquid partitioning with ethyl acetate (10 L x 3) followed by n-butanol (10 L x 3) solvents, to yield ethyl acetate (4.7 g) and butanol (108 g) extracts, respectively, after solvent removal in vacuo.

[00119] Analytical HPLC

[00120] All analyses are conducted on a Luna C18 column (250 x 4.6 mm i.d., 5 µM; Phenomenex) with a flow rate at 0.75 mL/min and injection volume of 20 µL. A gradient solvent system consisting of solvent A (0.1% aqueous trifluoroacetic acid) and solvent B (methanol, MeOH) is used as follows: 0-10 min, 10 % to 15 % B; 10-20 min, 15 % B; 20-40 min, 15 % to 30 % B; 40-55 min, 30 % to 35 % B; 55-65 min, 35 % B; 65-85 min, 35 % to 60 % B; 85-90 min, 60 % to 100 % B; 90-93 min, 100 % B; 93-94 min, 100 % to 10 % B; 94- 104 min, 10 % B. Figs 1A and 1B show the HPLC-UV profiles of the butanol extract and all of the isolated phenolics (combined into one solution/injection), respectively.

[00121] Isolation of Compounds from the MS Butanol Extract

[00122] The butanol extract (108 g) is extracted with methanol (100mL x 3) to afford methanol soluble (57 g; dark-brown powder) and methanol insoluble (51 g; off-white powder) fractions. Analytical HPLC analyses of the methanol soluble extract revealed a number of peaks characteristic of phenolic compounds at 220, 280 and 360 nm (see above for details of methodology; see Fig 1A for chromatogram). Therefore, this fraction is selected for further purification by repeated chromatography on a Sephadex™ LH-20 column (4.5 x 64 cm), eluting with a gradient system of MeOH: H₂O (3:7 v/v to 7:3 v/v to 100:0 v/v), and then with acetone: H₂O (7:3 v/v). Based on analytical HPLC profiles, twelve combined fractions, Fr. 1-12, are obtained. Fr. 4 (1.5 g) is subjected to column chromatography on a Sephadex™ LH-20 column (4.5 x 64 cm) using a gradient solvent system of MeOH: H₂O (3:7 v/v to 7:3 v/v) to afford twelve sub-fractions, Fr. 4.1-4.12. These are individually subjected to a series of semi-prep HPLC separation using a Waters Sunfire Prep™ C₁₈ column (250 x 10 mm i.d., 5 µm; flow 2 mL/min) and eluting with a MeOH:H₂O gradient system to yield compounds **1** (4.6 mg), **3** (3.8 mg), **5** (4.0 mg), **6** (41.6 mg), **7** (6.6 mg), **11** (3.5 mg), **15** (0.3 mg), **16** (0.8 mg), **18** (0.2 mg), **20** (1.3 mg), **22** (1.5 mg) and **23** (3.0 mg). Similarly, Fr. 5 (0.47 g) is purified by semi-prep HPLC using a Waters XBridge Prep C₁₈ column (250 x 19 mm i.d., 5 µm; flow 3.5 mL/min) and a gradient solvent system of MeOH:H₂O to afford four subfractions Fr. 5.1-5.4. These subfractions are separately subjected to a combination of semi-prep HPLC and/or Sephadex™ LH-20 column chromatography with gradient solvents systems of MeOH:H₂O to afford compounds **2** (1.9 mg), **4** (1.9 mg), **8** (2.0 mg), **9** (2.3 mg), **14** (2.5 mg), **17** (2.4 mg), **19** (1.8 mg) and **21** (1.3 mg). Similarly, Fr. 6 (0.2 g) afforded compounds **12** (1.4 mg) and **13** (1.3 mg) and Fr. 11 yielded compound **10** (4.8 mg).

[00123] Isolation of Compounds from the MS Ethyl Acetate Extract

[00124] Maple syrup (grade C, 20 L) is provided by the Federation of Maple Syrup Producers of Quebec (Canada). The syrup (20 L) is kept in the freezer (-20°C), until extraction when it is subjected to liquid-liquid partitioning with ethyl acetate (10 L x 3) followed by n-butanol (10 L x 3) solvents, to yield ethyl acetate (4.7 g) and butanol (108 g) extracts, respectively, after solvent removal *in vacuo*. The ethyl acetate extract (4.7 g) is subjected to a series of chromatographic isolation procedures using XAD-16, silica gel, Sephadex™-LH 20, and C-18 column chromatography. Semi-purified fractions obtained from these columns are then further subjected to prep-HPLC to yield twenty pure compounds.

[00125] Identification of Compounds

[00126] All of the isolated compounds are identified by examination of their ¹H and/or ¹³C NMR and mass spectral data, and by comparison of these to published literature reports, when available (Table 3). The NMR data for compounds **7**, **12**, and **13** are provided here.

Table 3**Compounds identified in a butanol extract of Canadian maple syrup (MS)**
















	Identification	Structure
1	lyoniresinol	
2	Secoisolariciresinol	
3	dehydroconiferyl alcohol	
4	5'-methoxydehydroconiferyl alcohol	
5	guaiacylglycerol- β -O-4'-coniferyl alcohol (1,3-Propanediol, 1-(4-hydroxy-3-methoxyphenyl)-2-[4-[(1E)-3-hydroxy-1-propenyl]-2-methoxyphenoxy]-, (1R,2R)-)	
6	guaiacylglycerol- β -O-4'-dihydroconiferyl alcohol 1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]-propane-1,3-diol	
7	[3-[4-[(6-deoxy- α -L-mannopyranosyl)oxy]-3-methoxyphenyl)methyl]-5-(3,4-dimethoxyphenyl)dihydro-3-hydroxy-4-(hydroxymethyl)-2(3H)-furanone	

Table 3 (continued)

8	Scopoletin	
9	Fraxetin	
10	(E)-3,3'-dimethoxy-4,4'-dihydroxystilbene	
11	2-hydroxy-3',4'-dihydroxyacetophenone	
12	1-(2,3,4-trihydroxy-5-methylphenyl)-ethanone	
13	2,4,5-trihydroxyacetophenone	
14	Catechaldehyde	
15	Vanillin	
16	Syringaldehyde	

Table 3 (continued)

17	gallic acid	
18	trimethyl gallic acid methyl ester	
19	syringic acid	
20	Syringenin	
21	(E)-coniferol	
22	C-veratroylglycol	
23	Catechol	
54	Quebecol	

[00127] In another embodiment, there are disclosed thirty phenolics obtained from an ethyl acetate extract of maple syrup (MS-EtOAc).

[00128] Chemicals and Reagents. All solvents are of ACS or HPLC grade and are obtained from Sigma-Aldrich through Wilkem Scientific (Pawcatuck, RI). Sephadex LH-20, ascorbic acid, butylated hydroxytoluene (BHT), and diphenylpicrylhydrazyl (DPPH) reagent are purchased from Sigma-Aldrich (St. Louis, MO).

[00129] Extraction and Isolation of Maple Syrup Ethyl Acetate (MS-EtOAc) Compounds. Maple syrup (grade C, 20 L) is provided by the Federation of Maple Syrup Producers of Quebec (Canada). The maple syrup is shipped and kept frozen upon delivery. The maple syrup is subjected to liquid-liquid partitioning with ethyl acetate (10 L x 3) to yield a dried ethyl acetate extract (MS-EtOAc; 4.7 g) after solvent removal in *vacuo*. The MS-EtOAc (4.5 g) is initially purified on a Sephadex LH-20 column (4 x 65 cm) with a gradient system of MeOH/H₂O (3:7 to 1:0, v/v) to afford seven fractions, A1-A7. Fraction A1 (2.08 g) is then chromatographed on a C18 MPLC column (4 x 37 cm) eluting with a gradient system of MeOH/H₂O (3:7 to 1:0, v/v) to afford sixteen subfractions, B1-B16. These sub-fractions are individually subjected to a series of semi-preparative HPLC separations using a Phenomenex Luna C18 column (250 x 10 mm i.d., 5 µm, flow = 2 mL/min) with different isocratic elution systems of MeOH/H₂O to afford compounds **25** (0.9 mg), **26** (2.5 mg), **27** (0.8 mg), **28** (0.5 mg), **29** (17.5 mg), **730** (0.7 mg), **31** (1.1 mg), **32** (3.9 mg), **33** (1.1 mg), **34** (2.1 mg), **35** (2.8 mg), **36** (3.2 mg), **38** (2.4 mg), **39** (5.2 mg), **40** (0.8 mg), and **53** (0.5 mg). Similarly, fraction A3 (0.71 g) is purified by semi-preparative HPLC using a Waters XBridge Prep C18 column (250 x 19 mm i.d., 5 µm; flow = 3.5 mL/min) and a gradient solvent system of MeOH/H₂O to afford four subfractions C1-C4. These subfractions are separately subjected to semi-preparative HPLC with isocratic solvents systems of MeOH/H₂O to afford compounds **24** (2.2 mg), **37** (4.5 mg), **42** (4.5 mg), **43** (2.2 mg), **44** (4.2 mg), **50** (3.7 mg), and **51** (1.1 mg). Similarly, fraction A4 (0.097 g) is purified by semi-preparative HPLC to afford

compounds **41** (1.4 mg), **45** (2.6 mg), **46** (8.0 mg), **47** (0.4 mg), and **49** (3.2 mg) and subfraction A5 (0.022 g) yielded compounds **48** (3.6 mg) and **52** (1.1 mg).

Table 4

Total Compounds isolated from an Ethyl Acetate Extract of Canadian Maple Syrup (MS-EtOAc)

compd	Identification
1	Lyoniresinol
2	Secoisolariciresinol
6	1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]-propane-1,3-diol (guaiaacylglycerol- β -O-4'-dihydroconiferyl alcohol)
8	Scopoletin
22	C-veratroylglycol
24	5-(3'',4''-dimethoxyphenyl)-3-hydroxy-3-(4'-hydroxy-3'-methoxybenzyl)-4-hydroxymethyl-dihydrofuran-2-one*
25	(<i>erythro</i> , <i>erythro</i>)-1-[4-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-dimethoxyphenyl]-1,2,3-propanetriol*
26	(<i>erythro</i> , <i>threo</i>)-1-[4-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-dimethoxyphenyl]-1,2,3-propanetriol*
27	(<i>threo</i> , <i>erythro</i>)-1-[4-[(2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-1,2,3-propanetriol ^a
28	(<i>threo</i> , <i>threo</i>)-1-[4-[(2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-1,2,3-propanetriol ^a
29	<i>threo</i> -guaiaacylglycerol- β -O-4'-dihydroconiferyl alcohol
30	<i>erythro</i> -1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2,6-dimethoxyphenoxy]-1,3-propanediol ^a
31	2-[4-[2,3-dihydro-3-(hydroxymethyl)-5-(3-hydroxypropyl)-7-methoxy-2-benzofuranyl]-2,6-dimethoxyphenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol
32	Acernikol
33	leptolepisol D ^a
34	buddlenol E ^a
35	(1S, 2R)-2-[2,6-dimethoxy-4-[(1S,3aR,4S,6aR)-tetrahydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-1H,3H-furo[3,4-c]furan-1-yl]phenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol ^a
36	Syringaresinol
37	isolariciresinol ^a
38	icaraside E4 ^a
39	sakuraresinol ^a
40	1,2-diguaiacyl-1,3-propanediol ^a
41	2,3-dihydroxy-1-(3,4-dihydroxyphenyl)-1-propanone*
42	2,3-dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-propanone ^a
43	3-Hydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)propan-1-one ^a
44	dihydroconiferyl alcohol
45	4-acetylcatechol ^a
46	3',4',5'-trihydroxyacetophenone ^a
47	3,4-dihydroxy-2-methylbenzaldehyde
48	protocatechuic acid
49	4-(dimethoxymethyl)-pyrocatechol ^a
50	Tyrosol
51	isofraxidin ^a
52	4-hydroxycatechol ^a
53	phaseic acid ^a

^aFirst report from maple syrup

*New compounds

[00130] Preparation of preparation of a food-grade approved extract from maple syrup.

[00131] According to another embodiment of the present invention, there is disclosed a food grade extract from maple tree, including maple tree parts as well as syrup (e.g. Maple Syrup-XAD extract). The generation of the extract requires the utilization of non-food grade solvents and methods, a 'food-grade approved' phenolic-enriched extract of maple syrup for future nutraceutical applications is prepared. Towards this end, the maple syrup methanol extract (MS-MeOH) may be prepared using a FDA-food grade resin, such as polymeric resins that include but are not limited to styrene and divinylbenzene resins, and styrene-divinylbenzene (SDVB) cross-linked copolymer resin. Examples of such resins include but are not limited to Amberlite™ XAD-4 (divinylbenzene copolymer), XAD-2 (polystyrene copolymer resin), XAD-7 (aliphatic ester), XAD 7HP (aliphatic ester), XAD16 (polystyrene-divinylbenzene), XAD16HP (polystyrene-divinylbenzene), XAD761(Crosslinked phenol-formaldehyde polycondensate), XAD1180 (Polydivinylbenzene), XAD1600 (polystyrene-divinylbenzene), FPx-66 (macroreticular aromatic polymer), XFS-4257, XFS-4022 (unfunctionalized polystyrene beads), XUS-40323 and XUS-40322. Amberlite™ strong anion exchange (SAX) resin, Amberlite™ WAX Resin, a pentafluorophenyl derivatized silica gel, HLB (hydrophobic-lipophilic balanced) type SILIaPrepX phase, strong anion exchange (SAX) resin on silica or mixed-mode strong anion exchange (SAX)-C₁₈, an aqueous C₁₈ phase, a C₁₈ phase, a C₁₈ type SILIaPrepX™ phase, diatomaceous earth. According to an embodiment of the present invention, the polymeric may be Amberlite™ XAD-16 (Sigma) and adsorption chromatography is performed by adsorbing the maple syrup on the XAD-16 resin column, eluted with copious amounts of water to remove the natural sugars, then finally eluted with MeOH to yield the maple syrup methanol extract (MS-MeOH) after solvent removal *in vacuo*. Elution may also be effected with other solvents, which include ethanol.

[00132] 1. 1 Kg of Amberlite™ XAD-16 (Sigma) soaked overnight and packed in a large glass column

- [00133]** 2. Eluted the XAD-16 column with copious amounts of water.
- [00134]** 3. Adsorb a certain volume (to be determined; ca. 500 mL; (make sure it is not over loaded),) of maple syrup which was previously diluted in water so that the solution is not too sticky.
- [00135]** 4. Leave maple syrup column on XAD-16 column for ca. 1 h.
- [00136]** 5. Elute the column with copious amounts of water to remove sugar (check the eluent for color).
- [00137]** 6. Elute with methanol to remove phenolics.
- [00138]** 7. Dry the methanol fraction using a rotary evaporator *in vacuo*, the temperature of the water bath should be set from 37°C and should not exceed 40°C.
- [00139]** 8. The dried sample is maple syrup XAD extract also known as MSX.
- [00140]** 9. Repeat the steps to prepare enough quantities.
- [00141]** According to another embodiment, there is also disclosed a process for the extraction of polyphenolic compounds from maple syrup. The process comprises contacting an adsorbent material having a maple syrup polyphenolic fraction adsorbed thereon with an organic solvent, for a time sufficient and for a number of times sufficient, to elute and collect said maple syrup polyphenolic fraction.
- [00142]** According to an embodiment, the time sufficient may be about 30 minutes. The number of time sufficient is from about 1 time to about 3 times.
- [00143]** According to another embodiment, the maple syrup mixture is adsorbed on the adsorbent material for a time sufficient to adsorb the polyphenolic fraction on the adsorbent material, and the mixture comprises maple syrup diluted in water.
- [00144]** The time sufficient to adsorb said polyphenolic fraction is from about 12 to about 20 hours, or from about 12 to about 19 hours, or from about 12

to about 18 hours, or from about 12 to about 17 hours, or from about 12 to about 16 hours, or from about 12 to about 15 hours, or from about 12 to about 14 hours, or from about 12 to about 13 hours. The time sufficient to adsorb said polyphenolic fraction may be 12, 13, 14, 15, 16, 17, 18, 19, 20 hours. Preferably, the time is 16 hours.

[00145] Examples of absorbent material include but are not limited to Amberlite™ XAD-4 (divinylbenzene copolymer), XAD-2 (polystyrene copolymer resin), XAD-7 (aliphatic ester), XAD 7HP (aliphatic ester), XAD16 (polystyrene-divinylbenzene), XAD16HP (polystyrene-divinylbenzene), XAD761(Crosslinked phenol-formaldehyde polycondensate), XAD1180 (Polydivinylbenzene), XAD1600 (polystyrene-divinylbenzene), FPx-66 (macroreticular aromatic polymer), XFS-4257, XFS-4022 (unfunctionalized polystyrene beads), XUS-40323 and XUS-40322. Amberlite™ strong anion exchange (SAX) resin, Amberlite™ WAX Resin, a pentafluorophenyl derivatived silica gel, HLB (hydrophobic-lipophilic balanced) type SILlaPrepX phase, strong anion exchange (SAX) resin on silica or mixed-mode strong anion exchange (SAX)-C₁₈, an aqueous C₁₈ phase, a C₁₈ phase, a C₁₈ type SILlaPrepX™ phase, diatomaceous earth.

[00146] According to another embodiment, the process may further comprise the step of diluting the maple syrup in water prior prior to adsorption on said adsorbent material.

[00147] According to another embodiment, the process may further comprise the step of washing the adsorbent material with water prior to step a).

[00148] According to another embodiment, the process may further comprise step b) : heating the collected polyphenolic fraction to evaporate the organic solvent and obtain a dried polyphenolic fraction. Heating may be at a temperature of about 37°C to about 40°C.

[00149] According to another embodiment, the organic solvents suitable for the process of the present invention may be chosen from methanol, ethyl acetate, butanol, ethanol, methyl *tert*-butyl ether, and combinations thereof.

[00150] According to yet another embodiment, the process of the present invention may further comprise prior to step a) an extraction with a mixture of solids for extraction of a sugar from said maple syrup. For example, such extraction with a mixture of solids comprises extraction with MgSO_4 , NaCl , and a solid absorbent. Preferably, the solid absorbent for this extraction may be chosen from an aminated silica resin, a C_{18} silica resin, or combinations thereof.

[00151] According to yet another embodiment, the process of the present invention may further comprising prior to step a) a liquid-liquid extraction of the maple syrup. For example, the liquid-liquid extraction may comprise an ethyl acetate extraction, a butanol extraction, or combinations thereof, followed by adsorption on a silicon dioxide (SiO_2)/magnesium oxide (MgO) solid phase having a ratio of about 85% SiO_2 and about 15% MgO (Florisil®).

[00152] According to yet another embodiment, there is disclosed an extract obtained from the process of the present invention.

[00153] Preparation of Maple Syrup Butanol Extract without sugar (MS-BuOH without sugar)

[00154] According to another embodiment of the present invention, there is disclosed an MS butanol extract without sugar.

[00155] 1. A known volume of maple syrup (based on the size of your separatory funnel) is subjected to liquid-liquid partitioning with n-butanol (1:1 v/v; 3 times). The maple syrup is diluted with water before partitioning since it is too sticky. (Usually we add around 300 ml water to 1L maple syrup).

[00156] 2. Combine the butanol fraction and dry *in vacuo* as previously described.

[00157] 3. The dried butanol fraction will be still very sticky and we usually freeze-dry or vacuum dry to make sure it has a powdery consistency

[00158] 4. The dried butanol extract powder is reconstituted in methanol and the filtered to remove the white solid i.e. sugars. The liquid portion is part is dried *in vacuo* as previously described.

[00159] 5. After removing the solvent from the liquid part, add certain methanol to remove sugar again. Repeat filtering and drying.

[00160] 6. The final dried extract is the MS-BuOH extract without sugar.

[00161] 7. Repeat steps to prepare enough quantities

[00162] **Preparation of Maple Syrup Butanol Extract with sugar (MS-BuOH with sugar)**

[00163] According to another embodiment of the present invention, there is disclosed an MS butanol extract without sugar.

[00164] Follow steps 1-3 above. In this case, the sugars are not removed with methanol.

[00165] Determination of total phenolic content by the Folin-Ciocalteu method

[00166] The total phenolic contents of the maple syrup extracts are determined according to the Folin-Ciocalteu method and is measured as gallic acid equivalents (GAEs). Briefly, the extracts were diluted 1:100 with methanol/H₂O (1:1, v/v), and 200 µL of each sample was incubated with 3 mL of methanol/H₂O (1:1, v/v) and 200 µL of Folin-Ciocalteu reagent for 10 min at 25°C. After this, 600 µL of 20 % Na₂CO₃ solution was added to each tube and vortexed. Tubes were further incubated for 20 min at 40°C and after, incubation; samples were immediately cooled in an ice bath to room temperature. Samples and standard (gallic acid) were processed identically. The absorbance was determined at 755 nm, and final results were calculated from the standard curve obtained from a Spectramax plate reader.

[00167] **Methods of solvent removal**

[00168] According to some embodiments, solvent removal from the extracts of the present invention may be effected *in vacuo*. However, other known techniques may be employed, such as atomization, lyophilization, evaporation, crystallization, dehydration, precipitation, centrifugation, or any other suitable

process to eliminate the aqueous phase from any of the extracts of the present invention.

Table 5

Presence and relative levels of pure isolated phenolic compounds in the different maple syrup extracts*

Compound	Name	MS-BuOH	MS-EtOAc	MS-MeOH
1	Lyoniresinol	+	+	+
2	Secoisolariciresinol	+	+	+
3	2,3-dihydro-3-(hydroxymethyl)-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-5-benzofuranpropanol (dihydrodehydrodiconiferyl alcohol)	+		+
4	5'-methoxydehydroconiferyl alcohol	+		
5	1,3-propanediol, 1-(4-hydroxy-3-methoxyphenyl)-2-[4-[(1E)-3-hydroxy-1-propenyl]-2-methoxyphenoxy]-(1R,2R)	+		+
6	1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propane-1,3-diol (guaiacylglycerol- β -O-4'-dihydroconiferyl alcohol)	+	+	+
7	3-[(4-[(6-dexoy- α -L-mannopyranosyl)oxy]-3-methoxyphenyl)-5-(3,4-dimethoxyphenyl)dihydro-3-hydroxy-4-(hydroxymethyl)-2(3H)-furanone	+		+
8	Scopoletin	+	+	+
9	Fraxetin	+		+
10	(E)-3,3'-dimethoxy-4,4'-dihydroxy stilbene	+		+
11	2-Hydroxy-3',4'-dihydroxyacetophenone	+		+
12	1-(2,3,4-trihydroxy-5-methylphenyl)-ethanone	+		+
13	2,4,5-trihydroxyacetophenone	+		
14	Catechaldehyde	+		+
15	Vanillin	+	+	+
16	Syringaldehyde	+		+
17	Gallic acid	+		+
18	trimethyl gallic acid methyl ester	+		
19	Syringic acid	+	+	+
20	Syringenin	+		+
21	(E)-coniferyl alcohol (coniferol)	+		+

Table 5 (continued)

Compound	Name	MS- BuOH	MS- EtOAc	MS- MeOH
22	C-veratroylglycol	+	+	+
23	1,2-benzenediol (catechol)	+		+
24	5-(3",4"-dimethoxyphenyl)-3-hydroxy-3-(4'-hydroxy-3'-methoxybenzyl)-4-hydroxymethyl-dihydrofuran-2-one		+	+
25	(erythro, erythro)-1-[4-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-dimethoxyphenyl]-1,2,3-propanetriol		+	+
26	(erythro, threo)-1-[4-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-dimethoxyphenyl]-1,2,3-propanetriol		+	+
27	(threo, erythro) 1-[4-[(1R,2R)-2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3-methoxyphenyl]-1,2,3-propanetriol		+	+
28	(threo, threo) 1-[4-[(1R,2R)-2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3-methoxyphenyl]-1,2,3-propanetriol		+	+
29	<i>Threo</i> -guaiacylglycerol- β -O-4'-dihydroconiferyl alcohol		+	+
30	<i>erythro</i> -1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2,6-dimethoxyphenoxy]-1,3-propanediol		+	
31	2-[4-[(2S,3R)-2,3-dihydro-3-(hydroxymethyl)-5-(3-hydroxy propyl)-7-methoxy-2-benzofuranyl]-2,6-dimethoxyphenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol		+	+
32	Acernikol		+	+
33	Leptolepisol D		+	+
34	Buddenol E		+	+
35	(1S, 2R)-2-[2,6-dimethoxy-4-[(1S,3aR,4S,6aR)-tetrahydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-1H,3H-furo[3,4-c]furan-1-yl]phenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol		+	+
36	Syringaresinol		+	+
37	Isolariciresinol		+	+
38	Icariside E4		+	+
39	Sakuraresinol		+	+
40	1,2-diguaiacyl-1,3-propanediol		+	+

Table 5 (continued)

Compound	Name	MS- BuOH	MS- EtOAc	MS- MeOH
41	2,3-dihydroxy-1-(3,4- dihydroxyphenyl)-1-propanone		+	+
42	2,3-dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-propanone		+	+
43	3-hydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)propan-1-one		+	+
44	Dihydroconiferyl alcohol		+	+
45	4-hydroxycatechol		+	+
46	3',4',5'-Trihydroxyacetophenone		+	+
47	3,4-dihydroxy-2-methylbenzaldehyde		+	
48	Protocatechuic acid		+	+
49	4-(dimethoxymethyl)-pyrocatechol		+	+
50	Tyrosol		+	+
51	Isofraxidin		+	+
52	4- acetylcatechol		+	+
53	phaseic acid		+	
54	Quebecol	+		
55	Ferulic acid			+
56	<i>p</i> -coumaric acid			+
57	Catechin			+
58	Epicatechin			+

[00169] The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLE 1

Assessment of metabolic syndrome-preventing effects of the nutriprotective diet

[00170] The objective of the current example is to evaluate the metabolic syndrome-improving effects of the nutriprotective diet.

[00171] Materials and methods

[00172] A maple syrup extract is used which has been prepared from the amber grade of maple syrup by treatment with n-butanol which may be useful to prepare an extremely low-sugar product. A total amount of 50 g butanol extract, 20 mg butanol extract basis, is necessary for 5 repetitions of a 60-day-feeding trial with 8 rats fed on 20 g diet/capita/day.

[00173] Feeding

[00174] Male rats (Wistar) are fed on an AIN93G-based high-fat diet with 0.1% butanol extract of maple syrup (n=8) or on the same diet without the extract (n=8) for 2 months. During the feeding, daily body weight gains and diet intakes are measured every day.

[00175] Dissection

[00176] Each rat after the feeding is subjected to dissection for sampling the systemic blood, small-intestinal epithelia, liver and adipose tissue.

[00177] Blood chemistry analysis

[00178] Systemic blood qualities are analyzed for 20–50 items.

[00179] Genomics

[00180] Transcriptomics is carried with for total RNA samples from each organ or tissue by DNA microarray analysis using affymetrix gene chip.

[00181] Results

[00182] The use of the butanol extract of maple syrup as a supplement to high-fat (or high-calorie) diets reduces the risk of metabolic syndromes by modulating the lipid and/or sugar metabolic pathways.

EXAMPLE 2

GLOBAL ANALYSIS OF HEPATIC GENE EXPRESSION PROFILES IN DIABATES MODEL KK-A_y MICE

[00183] Now referring to Fig. 8, the purpose of this study is to elucidate the effect of butanol extract of maple syrup (MSE, as described above) on the liver of T2DM model mice – KK-A_y mice (diabetic mice). Male KK-A_y mice, aged 4 weeks, as T2DM model mice for investigation of obesity, hyperglycemia and insulin resistance are selected and separated into two experimental groups as shown in Fig. 8: 16 males, control group (n=8) fed AIN-93G diet, and experimental group (N=8) fed MSE (AIN-93G diet + 0.1% MSE). The animals are prefed the same normal diet for 7 days, then fed the experimental diets for 43 days. They are fasted for 16 hours and liver and serum samples are collected.

[00184] Now referring to Figs. 9 to 11. Measurement of serum glucose, insulin and glycoalbumin levels show that MSE intake tends to improve hyperglycemia (Fig. 9). Furthermore, as shown in Fig. 10, MSE intake significantly activates the lipid β -oxidation in the liver, resulting in increased concentration of total ketone bodies. Furthermore, as shown by the measurement of the activity of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Fig. 11), MSE intake significantly ($p < 0.01$ and $p < 0.05$ respectively) ameliorates hepatopathy.

[00185] As summarized in Fig. 12, feeding of MSE to KK-A_y mice results in improved hyperglycemia, activation of β -oxidation, and mitigation of hepatopathy.

[00186] Next, hepatic transcriptome analysis is performed with Affymetrix Genechip (Mouse Genome 430 2.0). Microarrays are performed and results are normalized with the distribution free weighted method (DFW). The two experimental groups clustered separately from one another (Fig. 13), indicating that there are noticeable differences in gene expression between the two groups. Furthermore, there are 736 significantly up-regulated genes and 1078 significantly down-regulated genes in the MSE group ($FDR < 0.05$).

[00187] The significantly differentially expressed genes are then analyzed by gene annotation enrichment analysis, and insulin signaling is focussed on by verifying the statistical significance of the genes of this signalling pathway, as well as by immunoblotting.

[00188] With respect to gene annotation enrichment analysis, as shown in Figs. 15 to 18, the results show significant changes in lipid metabolism, inflammation and immunity, material transport, amino acid metabolism, oxidoreduction, as well as epithelial cell development, chemical homeostasis, and cell redox homeostasis. With respect to lipid metabolism-related genes, MSE intake appears to down-regulate lipid accumulation in the liver (Fig. 16). With respect to inflammation and immunity related genes, MSE appears to suppress the onset of inflammation in the liver (Fig. 17). As summarized in Fig. 18, the suppression of lipid accumulation in the liver is consistent with an increase in the total ketone bodies in serum, while the suppression of inflammation is consistent with reduction in serum AST and ALT.

[00189] Next, as shown in Figs. 19 to 24 the insulin signalling pathway is analyzed (Fig. 19). Immunoblotting of insulin receptor and phospho-insulin receptor (IR) beta subunit in each group reveals an increase in phosphorylation of the insulin receptor beta subunit (Fig. 20). Immunoblotting of the insulin receptor substrate 2 (IRS2) reveals an increase in protein expression of IRS2 in MSE treated animals. Immunoblotting of the protein kinase B (Akt) protein and phosphoprotein revealed an increase phosphorylated Akt in the MSE treated group (Fig. 22). As shown in Fig. 23, MSE intake by KK-Ay mice lead to an overall improvement of the insulin signalling function of KK-Ay mice liver. This result is consistent with the observed downregulation of plasma glycosylated albumin for suppression of hyperglycemia. As shown in Fig. 24, the suggested mechanism of the effect of MSE on the liver of KK-Ay mice is through decrease lipid accumulation, improved insulin sensitivity, increased β -oxidation and decreased inflammation.

EXAMPLE 3**ASSESSMENT OF METABOLIC SYNDROME-PREVENTING EFFECTS OF A MAPLE SYRUP EXTRACT SUPPLEMENTED HIGH- FAT DIET**

[00190] Now referring to Figs. 25 to 31, the aim of this study is to clarify the liver-protecting effect of maple syrup using mice fed with a high-fat diet with or with supplementation with a maple syrup extract (MSX). The MSX extract is prepared as described above with the use of a food-grade approved resin XAD-16 to prepare a food grade approved extract from maple syrup. The MSX extract is prepared from 50 L of maple syrup. The experimental groups are defined in Table 6 below:

Table 6
Experimental groups and respective diets

Group	Diet
LFD	10%-fat diet
45F	45%-fat diet
45F+0.06MSX	45%-fat diet with 0.06% MSX
45F+0.12MSX	45%-fat diet with 0.12% MSX

LFD = low fat diet; 45F = high fat diet

[00191] As shown in Fig. 25, 3-week old C57/BL/6J male mice (N=4 in each group) are fed a low fat diet for 7 days, and then each group is switched to their respective experimental diet for 4 weeks (28 days). Liver and blood samples are collected at the end of the 4 week period. The results in Fig. 26 show that body weight increase and energy intake are the same between all 4 experimental groups.

[00192] However, as shown in Fig. 27, the level of plasma choline esterase is significantly decreased in animals treated with MSX. As shown in Fig. 28, the level of plasma AST, ALT and LDH all decrease in a dose dependent manner in the MSX treated groups, suggesting that MSX has a liver protecting effect, and that the liver-protecting factors are present in MSX.

[00193] As shown in Fig. 29, the total plasma protein levels, albumin levels are approximately unchanged between each group, and the blood urea nitrogen levels appears slightly higher in the 0.12% MSX group. As shown in Fig. 30, total

plasma potassium, calcium levels, total bilirubin and alkaline phosphatase levels do appears to trend toward the low fat diet levels in the 0.12% MSX group. And the total bilirubin level do appear to trend downward toward the low fat diet levels for each MSX treated group. In conclusion, there results show that the choline esterase levels are significantly decreased in the MST diet groups, and that AST, ALT and LDH levels are decreased in a dose dependent manner in the MSX diet groups. These results indicate that MSX has a liver protecting effects. To confirm these results, a new experiment is being carried out, in which experimental groups of each n=14 animals are being treated with low fat diet, a high fat diet, or a high fat diet supplemented with 0.6% MSX for a total of 8 weeks.

EXAMPLE 4

PREPARATION OF PREPARATION OF A FOOD-GRADE APPROVED EXTRACT FROM MAPLE SYRUP

[00194] Described is the methodology for the extraction of bioactive compounds from maple syrup without the sugar moiety, using two types of resin 1) FPX 66 and 2) XAD-16. These two resins both are divinylbenzene phases. The mechanism of adsorption of polyphenols on these phases is exclusively by means of hydrophobic interactions.

Methodology:

1. Dilution of a 5 L (6kg) portion of maple syrup with 2,1 L of deionized water.
2. Adsorption of the maple syrup mixture on 16,8 kg of wet Amberlite™ FPX66 or XAD-16 (5,0-6,7 kg dry mass) for 16 hours.
3. Wash of the column with deionized water (7 x 15 L).
4. Elution with denatured ethanol (3 x 15 L). Before each elution, let the ethanol in contact with the resin for 30 minutes.
5. Evaporation of ethanol on "rotary evaporator". The temperature of the water bath is set from 37°C and does not exceed 40°C.
6. Isolation of the MSX fraction (15,3 g).

7. Reconditioning of the resin with two portions of 10L of deionized water.

[00195] While preferred embodiments have been described above and illustrated in the accompanying drawings, it will be evident to those skilled in the art that modifications may be made without departing from this disclosure. Such modifications are considered as possible variants comprised in the scope of the disclosure.

CLAIMS:

1. An hepatoprotective composition for use in hepatoprotection comprising a down-regulation in the cellular amino acid metabolism of the liver consisting essentially of a resin purified maple syrup extract prepared with a styrene-divinyl-benzene cross-linked copolymer resin and eluted with ethanol, and a carrier, wherein the carrier and the maple syrup extract are not the same.
2. The hepatoprotective composition for use of any one of claim 1, wherein said composition comprises 0.06% to about 0.12% w/w of said maple syrup extract.
3. The hepatoprotective composition for use of any one of claims 1 or 2, wherein said composition comprises 0.06% to 0.12% w/w of the maple syrup extract and 99.94% to 99.88% w/w of a carrier, wherein the carrier and the maple syrup extract are not the same.
4. The hepatoprotective composition for use as claimed in any one of claims 1 - 3, wherein said hepatoprotective effect further comprises a down-regulation in the liver production of ammonia-forming enzymes.
5. The hepatoprotective composition for use as claimed in any one of claims 1 - 4, wherein said hepatoprotective effect further comprises a down-regulation of serum level of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and/or lactate dehydrogenase (LDH).
6. The hepatoprotective composition for use according to any one of claims 1 - 3 for use in the treatment or the mitigation of a liver disorder, an inflammatory disease, or diabetes in a subject in need thereof.
7. The hepatoprotective composition for use according to claim 6, wherein said liver disorder is selected from the group consisting of a metabolic syndrome,

a damaged hepatic function, a hepatic acid liver, a dyslipidemia, a hepatitis and a liver cancer.

8. The hepatoprotective composition for use of any one of claims 1 to 7, wherein said composition is a dietary supplement.
9. The hepatoprotective composition for use of any one of claims 1 to 8, wherein said carrier is a drinking liquid, an energy drink, a therapeutic drink, a protein rich drink or a coating on a dietary supplement.





Fig. 1


2/31



↑ No Change

Fig. 2


3/31



AST (GOT): aspartate aminotransferase

ALT (GPT): alanine aminotransferase

LDH : lactate dehydrogenase



LDH




Fig. 3

Comparison analysis → Differentially expressed genes (DEGs)



Functional classification of DEGs





Fig. 4

5/31



6/31




Fig. 6

7/31




Fig. 7

Experimental design

Animal: male KK-Ay mice, aged 4 weeks,
as T2DM model mice for investigation of obesity,
hyperglycemia and insulin resistance





Fig. 8

9/31



Mean ± SE (n = 8)

MSE intake tends to improve hyperglycemia

Fig. 9


Blood biochemistry ②

WO 2013/033828

CA 02846282 2014-02-24

PCT/CA2012/000832

10/31



**MSE intake significantly activates
the lipid b-oxidation in the liver**

Fig. 10

11/31




Fig. 11




Fig. 12

DNA microarray analysis

Array: Affymetrix Genechip Mouse Genome 430 2.0
Normalization: distribution free weighted method (DFW)

- Distinct clustering resulted
- Between-diet group comparison by rank products

Extraction of genes with significant changes in expression (FDR < 0.05)

Significantly up-regulated genes in MSE group: 736
Significantly down-regulated genes in MSE group: 1078




Fig. 13

14/31

Microarray data-based strategy of analysis

Significantly isolated genes

736 up-regulated genes
1078 down-regulated genes



Gene annotation
Enrichment analysis

Extraction of GO term (DAVID)



Hierarchical GO term (Quick GO)



GO terms classification

Insulin signaling

Statistical extraction of
involved genes

+

Immunoblotting

Fig. 14

15/31




Fig. 15

16/31




Fig. 16

17/31

Inflammation & Immunity related genes involved in:

- regulation of response to external stimulus
- response to unfolded protein
- acute-phase response
- activation of plasma proteins involved in acute inflammatory response
- complement activation, classical pathway
- complement activation, alternative pathway
- anti-apoptosis

Crp, Cd163, Orm1, Orm2, Orm3, Saa1, Saa4



Suppressed inflammation

C1qa, C1qb, C4b, C4bp, C8a, C8b, C9, Cfb, Cfh



Suppressed immunity

Down-regulation

MSE intake suppresses the onset of inflammation in liver

Fig. 17

18/31




Fig. 18

19/31





Fig. 19



21/31




Fig. 21




Fig. 22

23/31





Fig. 23

24/31

Expected mechanism of the effect of
MSE intake on the liver of KK-Ay mice






Fig. 25

26/31






Fig. 26

27/31




Fig. 27

28/31




Fig. 28

29/31




Fig. 29




Fig. 30

New experiment

C57BL/6J mice
male
3-week old
n = 14

Day-7

LFD

8 weeks

Start

Day 56

LFD
45F

45F+0.06MSX

31/31






Fig. 31


AST (GOT)



ALT (GPT)



LDH



(n = 8~9) (* $P < 0.05$)

AST (GOT): aspartate aminotransferase

ALT (GPT): alanine aminotransferase

LDH : lactate dehydrogenase